Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Regulatory News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

Share Price is delayed by 15 minutes
Get Live Data
1,460.00    44.00 (3.11%)
Bid:
1,453.00
Ask:
1,454.00
Spread: 1.00 (0.069%)
Market Cap: £3.10b
HIK Live PriceLast checked at - London Stock Exchange

Intraday Hikma Pharmaceuticals Share Chart

Director Declaration

29 Jul 2024 16:08

RNS Number : 2662Y
Hikma Pharmaceuticals Plc
29 July 2024
 

Hikma Pharmaceuticals PLC

Director Declaration

LONDON, 29 July 2024: Pursuant to Listing Rule 9.6.14, Hikma Pharmaceuticals PLC confirms that Victoria Hull, Senior Independent Non-Executive Director, has been appointed as a Non-Executive Director of IMI plc with effect from 1 August 2024.

- ENDS -

 

Enquiries:

 

Hikma Pharmaceuticals PLC

 

Helen Middlemist

Group Company Secretary

+44 20 7399 2760

 

Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY)

(LEI: 549300BNS685UXH4JI75)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RDNRLMATMTMTBRI
Date   Source Headline
3rd Mar 20222:44 pmRNSDirector/PDMR Shareholding
2nd Mar 20226:18 pmRNSTransaction in Own Shares
1st Mar 20225:57 pmRNSTransaction in Own Shares
28th Feb 20226:37 pmRNSTransaction in Own Shares
28th Feb 20225:16 pmRNSDirector/PDMR Shareholding
25th Feb 20225:58 pmRNSHikma Share Buyback Programme
25th Feb 20229:37 amRNSDirector/PDMR Shareholding
25th Feb 20227:00 amRNSShare Buyback Programme
24th Feb 20227:00 amRNSDirectorate Change
24th Feb 20227:00 amRNSFinal Results
23rd Feb 20229:23 amRNSHolding(s) in Company
16th Feb 202211:26 amRNSDirector/PDMR Shareholding
11th Feb 202210:17 amRNSHolding(s) in Company
8th Feb 202210:17 amRNSNotice of Results
3rd Feb 20227:00 amRNSHikma completes acquisition of Teligent
2nd Feb 202210:04 amRNSTotal Voting Rights
24th Jan 202212:45 pmRNSHolding(s) in Company
17th Jan 20227:00 amRNSAcquisition
12th Jan 20223:22 pmRNSHolding(s) in Company
10th Jan 20227:00 amRNSHikma Launches 503B Sterile Compounding Business
4th Jan 20222:55 pmRNSTotal Voting Rights
16th Dec 20211:42 pmRNSHolding(s) in Company
14th Dec 20212:34 pmRNSHolding(s) in Company
9th Dec 20217:00 amRNSRichter and Hikma sign agreement for denosumab
2nd Dec 202110:33 amRNSHolding(s) in Company
23rd Nov 20219:57 amRNSHolding(s) in Company
17th Nov 202110:35 amRNSHolding(s) in Company
4th Nov 20217:00 amRNSTrading Statement
1st Nov 20212:06 pmRNSTotal Voting Rights
4th Oct 20219:55 amRNSBlock listing Interim Review
27th Sep 20217:00 amRNSHikma acquires Custopharm
23rd Sep 20217:30 amRNSAdditional Listing
27th Aug 202112:15 pmRNSBio-Thera and Hikma announce exclusive agreement
6th Aug 20217:00 amRNSHalf-year Report
2nd Aug 20212:48 pmRNSTotal Voting Rights
19th Jul 20219:27 amRNSNotice of Results
5th Jul 20213:43 pmRNSTotal Voting Rights
2nd Jun 20211:14 pmRNSTotal Voting Rights
17th May 20214:00 pmRNSDirector/PDMR Shareholding
30th Apr 20217:00 amRNSHikma announces US FDA approval of KLOXXADO
30th Apr 20217:00 amRNSTrading Statement
26th Apr 202111:19 amRNSHolding(s) in Company
23rd Apr 20213:51 pmRNSResult of AGM
21st Apr 20217:00 amRNSHikma resumes launch of generic Advair Diskus®
13th Apr 202111:35 amRNSBlock listing Interim Review
13th Apr 20219:19 amRNSTotal Voting Rights
17th Mar 20212:29 pmRNSDirector/PDMR Shareholding
17th Mar 202111:08 amRNSAnnual Financial Report
15th Mar 202111:24 amRNSDirector/PDMR Shareholding
11th Mar 20211:36 pmRNSHikma and GSK agree to cease potential acquisition

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.